Drug Profile

BX 004

Alternative Names: BX-004; BX004-A

Latest Information Update: 08 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BiomX
Class Antibacterials; Bacteriophages
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pseudomonal infections
New Molecular Entity No

Highest Development Phases

Phase I/II Pseudomonal infections

Most Recent Events

25 Mar 2025 BiomX plans discussion with US FDA and other regulatory authorities for Pseudomonal infections in second half of 2025
04 Mar 2025 BiomX plans a phase II trial for Pseudomonal infections related to non-cystic fibrosis Bronchiectasis (Inhalation) (BiomX pipeline, March 2025)
18 Dec 2024 BiomX initiates a preclinical trial in Pseudomonal infections related to non-cystic fibrosis Bronchiectasis in Israel before December 2024 (BiomX pipeline, December 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com